WINDLAS BIOTECH LIMITED

During the Q1 FY27 Earnings Conference Call, management reported that Windlas Biotech achieved its highest quarterly revenue of INR 248 crores, reflecting an 18% year-on-year growth. The Indian pharma market experienced a volume growth of 3.4% in the same period. Management highlighted the ongoing commercialization of Plant 6, which is anticipated to enhance manufacturing capacity. The CEO, Komal Gupta, noted that the company completed a buyback of INR 47 crores and declared a dividend of INR 13 crores. The Generic Formulations CDMO vertical saw a 29% revenue growth, while the Exports vertical grew by 79%. Management emphasized a focus on long-term value creation and operational excellence, despite challenges in the Trade Generics segment due to the discontinuation of codeine-based products. The call concluded with management expressing gratitude for stakeholder support.

Management emphasized strong revenue growth and operational achievements.